Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia

Bantayehu Addis Tegegne,1 Agumas Alemu Alehegn,2 Mengistie Kassahun3 1Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 2Department of Pharmacy, Lumame Primary Hospital, Lumame, Ethiopia; Health Supplies and Laboratory Equipments Management Director...

Full description

Bibliographic Details
Main Authors: Tegegne BA, Alehegn AA, Kassahun M
Format: Article
Language:English
Published: Dove Medical Press 2024-04-01
Series:Integrated Pharmacy Research and Practice
Subjects:
Online Access:https://www.dovepress.com/drug-use-evaluation-of-tenofovirlamivudinedolutegravir-tld-fixed-dose--peer-reviewed-fulltext-article-IPRP
_version_ 1797201454250852352
author Tegegne BA
Alehegn AA
Kassahun M
author_facet Tegegne BA
Alehegn AA
Kassahun M
author_sort Tegegne BA
collection DOAJ
description Bantayehu Addis Tegegne,1 Agumas Alemu Alehegn,2 Mengistie Kassahun3 1Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 2Department of Pharmacy, Lumame Primary Hospital, Lumame, Ethiopia; Health Supplies and Laboratory Equipments Management Directorate Director, Amhara National Regional State Public Health Institute, Bahirdar, Ethiopia; 3Department of Public Health, College of Health Science, Debre Markos University, Debre Markos, EthiopiaCorrespondence: Bantayehu Addis Tegegne, Email bantayehuaddis.90@gmail.comBackground: A key strategy for quality improvement is drug use evaluation, which looks at the safe, appropriate use of medication principles. Tenofovir/Lamivudine/Dolutegravir (TLD-FDC) usage has not yet been sufficiently examined in published literature. The purpose of this study was to assess how TLD were used by HIV-positive patients Using WHO drug use evaluation standards in Lumame Primary Hospital, North West Ethiopia.Methods: Using WHO drug use evaluation standards, a retrospective study design was used to evaluate the appropriateness of TLD use. Systematic random sampling was utilized to gather patient medical records containing TLD. Accordingly, 100 records that met the inclusion criteria were selected and reviewed between April 1 and 15, 2021. Five criteria, namely, indication, dose, contraindication, drug interaction, and TLD safety monitoring were used to evaluate the appropriateness of TLD utilization.Results: 80% of patients were transited to TLD from other regimens. The median time on TLD was found to be 13 months with 9 months to 18 months IQR. The latest CD4 count as well as CD4 count at the initiation or transition of TLD was not done for 75% and 89% of the patients, respectively. 3/4 (75%) of the patients were found to have a scheduled medication refill history. TLD dosing, indications, and contraindications were found to be 100% appropriate. No, TLD safety monitoring tests were done for 21% of the patients in this study. However, viral load, liver/kidney function, and serum creatinine tests were done for 77% (95% CI: 74%– 79%), 5% (95% CI: 2%– 8%), and 14% (95% CI: 11%– 17%) of the patients, respectively. More over, In 93% (95% CI: 91%– 95%) of the patients, the TLD interaction was appropriate; in 7%, it was not. All recording, documenting, and reporting technologies were available and used efficiently, except for the Electronic Dispensing Tool.Conclusion: Generally, good adherence to national and WHO guidelines was obtained regarding dose, indication, and contraindications. However, improvement in safety monitoring tests and CPT utilization is recommended. Drug interactions satisfied the majority of the criteria’s threshold, while certain standards were not followed.Keywords: drug use evaluation, lumame primary hospital, Ethiopia, fixed dose combination: tenofovir/lamivudine/dolutegravir
first_indexed 2024-04-24T07:47:48Z
format Article
id doaj.art-569c7cdbe78948729742a8eb577bf0d7
institution Directory Open Access Journal
issn 2230-5254
language English
last_indexed 2024-04-24T07:47:48Z
publishDate 2024-04-01
publisher Dove Medical Press
record_format Article
series Integrated Pharmacy Research and Practice
spelling doaj.art-569c7cdbe78948729742a8eb577bf0d72024-04-18T18:02:45ZengDove Medical PressIntegrated Pharmacy Research and Practice2230-52542024-04-01Volume 13314292056Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West EthiopiaTegegne BAAlehegn AAKassahun MBantayehu Addis Tegegne,1 Agumas Alemu Alehegn,2 Mengistie Kassahun3 1Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 2Department of Pharmacy, Lumame Primary Hospital, Lumame, Ethiopia; Health Supplies and Laboratory Equipments Management Directorate Director, Amhara National Regional State Public Health Institute, Bahirdar, Ethiopia; 3Department of Public Health, College of Health Science, Debre Markos University, Debre Markos, EthiopiaCorrespondence: Bantayehu Addis Tegegne, Email bantayehuaddis.90@gmail.comBackground: A key strategy for quality improvement is drug use evaluation, which looks at the safe, appropriate use of medication principles. Tenofovir/Lamivudine/Dolutegravir (TLD-FDC) usage has not yet been sufficiently examined in published literature. The purpose of this study was to assess how TLD were used by HIV-positive patients Using WHO drug use evaluation standards in Lumame Primary Hospital, North West Ethiopia.Methods: Using WHO drug use evaluation standards, a retrospective study design was used to evaluate the appropriateness of TLD use. Systematic random sampling was utilized to gather patient medical records containing TLD. Accordingly, 100 records that met the inclusion criteria were selected and reviewed between April 1 and 15, 2021. Five criteria, namely, indication, dose, contraindication, drug interaction, and TLD safety monitoring were used to evaluate the appropriateness of TLD utilization.Results: 80% of patients were transited to TLD from other regimens. The median time on TLD was found to be 13 months with 9 months to 18 months IQR. The latest CD4 count as well as CD4 count at the initiation or transition of TLD was not done for 75% and 89% of the patients, respectively. 3/4 (75%) of the patients were found to have a scheduled medication refill history. TLD dosing, indications, and contraindications were found to be 100% appropriate. No, TLD safety monitoring tests were done for 21% of the patients in this study. However, viral load, liver/kidney function, and serum creatinine tests were done for 77% (95% CI: 74%– 79%), 5% (95% CI: 2%– 8%), and 14% (95% CI: 11%– 17%) of the patients, respectively. More over, In 93% (95% CI: 91%– 95%) of the patients, the TLD interaction was appropriate; in 7%, it was not. All recording, documenting, and reporting technologies were available and used efficiently, except for the Electronic Dispensing Tool.Conclusion: Generally, good adherence to national and WHO guidelines was obtained regarding dose, indication, and contraindications. However, improvement in safety monitoring tests and CPT utilization is recommended. Drug interactions satisfied the majority of the criteria’s threshold, while certain standards were not followed.Keywords: drug use evaluation, lumame primary hospital, Ethiopia, fixed dose combination: tenofovir/lamivudine/dolutegravirhttps://www.dovepress.com/drug-use-evaluation-of-tenofovirlamivudinedolutegravir-tld-fixed-dose--peer-reviewed-fulltext-article-IPRPdrug use evaluationlumame primary hospitalethiopiafixed dose combination: tenofovir/lamivudine/dolutegravir
spellingShingle Tegegne BA
Alehegn AA
Kassahun M
Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia
Integrated Pharmacy Research and Practice
drug use evaluation
lumame primary hospital
ethiopia
fixed dose combination: tenofovir/lamivudine/dolutegravir
title Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia
title_full Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia
title_fullStr Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia
title_full_unstemmed Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia
title_short Drug Use Evaluation of Tenofovir/Lamivudine/Dolutegravir (TLD) Fixed-Dose Combination for Initiation and Transition Among HIV-Infected Individuals Attending Lumame Primary Hospital, North West Ethiopia
title_sort drug use evaluation of tenofovir lamivudine dolutegravir tld fixed dose combination for initiation and transition among hiv infected individuals attending lumame primary hospital north west ethiopia
topic drug use evaluation
lumame primary hospital
ethiopia
fixed dose combination: tenofovir/lamivudine/dolutegravir
url https://www.dovepress.com/drug-use-evaluation-of-tenofovirlamivudinedolutegravir-tld-fixed-dose--peer-reviewed-fulltext-article-IPRP
work_keys_str_mv AT tegegneba druguseevaluationoftenofovirlamivudinedolutegravirtldfixeddosecombinationforinitiationandtransitionamonghivinfectedindividualsattendinglumameprimaryhospitalnorthwestethiopia
AT alehegnaa druguseevaluationoftenofovirlamivudinedolutegravirtldfixeddosecombinationforinitiationandtransitionamonghivinfectedindividualsattendinglumameprimaryhospitalnorthwestethiopia
AT kassahunm druguseevaluationoftenofovirlamivudinedolutegravirtldfixeddosecombinationforinitiationandtransitionamonghivinfectedindividualsattendinglumameprimaryhospitalnorthwestethiopia